NASDAQ:IMAB I-Mab (IMAB) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free IMAB Stock Alerts $1.76 0.00 (0.00%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$1.76▼$1.7950-Day Range$1.64▼$1.9052-Week Range$1.16▼$3.45Volume96,975 shsAverage Volume438,875 shsMarket Capitalization$142.44 millionP/E RatioN/ADividend YieldN/APrice Target$12.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get I-Mab alerts: Email Address I-Mab MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside594.1% Upside$12.25 Price TargetShort InterestHealthy1.61% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.97) to ($1.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.34 out of 5 starsMedical Sector489th out of 908 stocksBiotechnology Industry9th out of 19 stocks 3.5 Analyst's Opinion Consensus RatingI-Mab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageI-Mab has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.61% of the outstanding shares of I-Mab have been sold short.Short Interest Ratio / Days to CoverI-Mab has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in I-Mab has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldI-Mab does not currently pay a dividend.Dividend GrowthI-Mab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMAB. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for I-Mab this week, compared to 1 article on an average week.Search Interest23 people have searched for IMAB on MarketBeat in the last 30 days. This is an increase of 130% compared to the previous 30 days.MarketBeat Follows1 people have added I-Mab to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, I-Mab insiders have not sold or bought any company stock.Percentage Held by Insiders22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.38% of the stock of I-Mab is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for I-Mab are expected to grow in the coming year, from ($1.97) to ($1.72) per share.Price to Book Value per Share RatioI-Mab has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden out June 13; Kamala won’t replace him?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About I-Mab Stock (NASDAQ:IMAB)I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.Read More IMAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMAB Stock News HeadlinesApril 30, 2024 | prnewswire.comI-MAB Filed 2023 Annual Report on Form 20-FApril 16, 2024 | msn.comOmega Therapeutics CFO Joshua Reed to departMay 2, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”April 12, 2024 | markets.businessinsider.comI-MAB Buy Rating Justified by Strong Leadership and Promising PipelineApril 5, 2024 | prnewswire.comI-Mab to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceApril 4, 2024 | investing.comI-Mab completes divestiture of its Shanghai unit for $80 millionApril 2, 2024 | uk.finance.yahoo.comI-Mab Announces Closing of the Divestiture of Business Operations in ChinaApril 2, 2024 | prnewswire.comI-Mab Announces Closing of the Divestiture of Business Operations in ChinaMay 2, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”March 18, 2024 | finance.yahoo.comI-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 14, 2024 | finance.yahoo.comI-Mab Reports Full Year 2023 Financial Results and Business UpdateFebruary 22, 2024 | benzinga.comI-MAB Stock (NASDAQ:IMAB), Short Interest ReportFebruary 18, 2024 | seekingalpha.comI-Mab: Trading Below Net Cash With Multiple Upside OptionsFebruary 7, 2024 | marketwatch.comI-Mab to Divest Chinese Unit for Up to $80MFebruary 7, 2024 | msn.comI-Mab to divest Chinese assets amid rising geopolitical tensionsFebruary 7, 2024 | finance.yahoo.comI-Mab Signs Agreement to Divest its Assets and Business Operations in ChinaJanuary 11, 2024 | msn.comAsian Equities Traded in the US as American Depositary Receipts Advance in Thursday TradingDecember 31, 2023 | uk.finance.yahoo.comI-Mab (IMAB) interactive stock chart – Yahoo FinanceDecember 28, 2023 | benzinga.comI-MAB Stock (NASDAQ:IMAB) Dividends: History, Yield and DatesNovember 19, 2023 | finance.yahoo.comIndividual investors account for 41% of I-Mab's (NASDAQ:IMAB) ownership, while private equity firms account for 26%November 6, 2023 | finance.yahoo.comI-Mab Announces Participation at Jefferies and Piper Conferences in NovemberNovember 2, 2023 | msn.comI-Mab gains FDA breakthrough tag for kidney disease therapyNovember 2, 2023 | markets.businessinsider.comI-Mab:Felzartamab Granted Breakthrough Therapy Designation By FDA For Primary Membranous NephropathyNovember 2, 2023 | finance.yahoo.comFelzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)November 1, 2023 | finance.yahoo.comI-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023October 16, 2023 | finance.yahoo.comI-Mab Announces Phase 1 Data of Givastomig at ESMO 2023October 10, 2023 | finance.yahoo.comI-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503See More Headlines Receive IMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:IMAB CUSIPN/A CIK1778016 Webwww.i-mabbiopharma.com Phone86-21-6057-8000FaxN/AEmployees228Year FoundedN/APrice Target and Rating Average Stock Price Target$12.25 High Stock Price Target$25.00 Low Stock Price Target$6.00 Potential Upside/Downside+594.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.67 Quick RatioN/A Sales & Book Value Annual Sales$3.89 million Price / Sales36.62 Cash FlowN/A Price / Cash FlowN/A Book Value$2.93 per share Price / Book0.60Miscellaneous Outstanding Shares80,700,000Free Float62,867,000Market Cap$142.44 million OptionableOptionable Beta1.10 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Raj Kannan (Age 60)CEO & Director Dr. Jerry WangCo-Founder & Chief Scientific OfficerMr. Skelton JosephChief Financial OfficerMr. Tianyi ZhangVice President of Investor RelationsDr. Fernando J. Salle´s Ph.D.Senior VP and Head of U.S. & EU Business DevelopmentClaire XuHead of US siteMs. Min Yin (Age 54)Senior Vice President of Operations Dr. Louie Naumovski M.D.Ph.D., Interim Chief Medical OfficerMr. Tyler EhlerSenior Director of Investor RelationsMore ExecutivesKey CompetitorsSyros PharmaceuticalsNASDAQ:SYRSAEON BiopharmaNASDAQ:AEONSeres TherapeuticsNASDAQ:MCRBCervoMedNASDAQ:CRVORegulus TherapeuticsNASDAQ:RGLSView All CompetitorsInstitutional OwnershipNomura Holdings Inc.Sold 374,085 shares on 3/27/2024Ownership: 0.029%View All Institutional Transactions IMAB Stock Analysis - Frequently Asked Questions Should I buy or sell I-Mab stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMAB shares. View IMAB analyst ratings or view top-rated stocks. What is I-Mab's stock price target for 2024? 4 equities research analysts have issued 1 year target prices for I-Mab's stock. Their IMAB share price targets range from $6.00 to $25.00. On average, they expect the company's stock price to reach $12.25 in the next year. This suggests a possible upside of 594.1% from the stock's current price. View analysts price targets for IMAB or view top-rated stocks among Wall Street analysts. How have IMAB shares performed in 2024? I-Mab's stock was trading at $1.90 on January 1st, 2024. Since then, IMAB stock has decreased by 7.1% and is now trading at $1.7650. View the best growth stocks for 2024 here. Are investors shorting I-Mab? I-Mab saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,170,000 shares, an increase of 7.3% from the March 15th total of 1,090,000 shares. Based on an average daily volume of 436,300 shares, the short-interest ratio is presently 2.7 days. View I-Mab's Short Interest. What ETF holds I-Mab's stock? Invesco Nasdaq Future Gen 200 ETF holds 23,061 shares of IMAB stock, representing 0.58% of its portfolio. What other stocks do shareholders of I-Mab own? Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO), Enterprise Products Partners (EPD), G1 Therapeutics (GTHX), Intel (INTC) and Johnson & Johnson (JNJ). When did I-Mab IPO? I-Mab (IMAB) raised $100 million in an initial public offering (IPO) on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC served as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers. How do I buy shares of I-Mab? Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMAB) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.